trial · primary record
ATG dosing platform when combined with standard tacrolimus and mini methotrexate
Acute Leukemia
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 56 |
| Primary completion | 2028-11 |
| Primary endpoint | Rate of GRFS (graft versus host disease GVHD, relapse free survival) at one year post transplant. |
| Registry ID | NCT06265584 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:34:23.228Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06265584
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.